ABSTRACT
The rise in the use of cosmeceuticals among children and adolescents has created a new challenge for dermatologists, who are confronted with the task of advising young patients on the risks that these products can carry and the often questionable efficacy of these products. While some cosmeceuticals can be beneficial for this population when used correctly, such as broad‐spectrum sunscreen or specific anti‐acne agents, other products may not carry benefits for young skin and could even cause complications, particularly in young consumers who have skin conditions such as acne or atopic dermatitis. Many of the common ingredients in cosmeceutical products have had very limited (if any) studies conducted in pediatric populations, and much of the data regarding the efficacy claims and risks of these products must be inferred from studies in adult patients.
Keywords: acne, children, cosmeceuticals, pediatrics, skincare
1. Introduction
The use of cosmeceuticals, or products designed to provide esthetic benefits to the skin without a prescription, has exploded among the pediatric population, causing concern within the dermatology community. Cosmeceuticals fall in between cosmetics and drugs in terms of regulation by the United States Food and Drug Administration (FDA). Drugs are intended to treat a condition by altering physiologic processes, while cosmetics simply alter appearance [1]. Cosmeceuticals, a combination of the two, often contain active ingredients considered to be drugs, while claiming to provide aesthetic benefits typical of cosmetics [1, 2]. While cosmeceuticals that contain active ingredients are subjected to FDA regulation, the presence of active ingredients does not guarantee efficacy as not all active ingredients have known benefits. Cosmeceuticals are sold without a prescription by keeping the concentration of active ingredients below a threshold set by the FDA. The safety and tolerability of many of these ingredients and the effects on pre‐pubertal and pubertal skin is largely unstudied, and therefore the full risks of these ingredients to young consumers cannot be fully known.
The rise of social media has dramatically changed the landscape of available health information, particularly when it comes to skincare for children and adolescents. A 2021 study of teenage acne vulgaris patients found that 75% consulted social media for advice related to the treatment of their acne [3]. An analysis of the most popular videos related to acne treatment on TikTok, Instagram Reels, and YouTube Shorts found that 67.2% were made by users with no dermatologic medical background [4]. Additionally, cosmeceuticals were recommended far more than prescription treatments [4]. Teen spending on cosmetic and cosmeceutical products increased by 8% over the past year; the global skincare industry was valued at $146.7 billion in 2021 and is projected to reach a value of $273.3 billion in 2031 [5]. There is a massive financial incentive for cosmeceutical companies to drive demand for their products, and adolescents and pre‐teens have proven to be a key group to market toward.
Despite the rapidly expanding use of cosmeceuticals in the pediatric population, very limited research has been conducted to study these products in children and adolescents. Therefore, much of the data regarding cosmeceuticals in this population must be extrapolated from research in the adult population, often with questionable and irreproducible data from studies conducted by the cosmetics industry. This review investigates the safety concerns, efficacy, and uses of the most common cosmeceutical categories in the pediatric population. The cosmeceuticals discussed in this review are among the most popular featured on social media, in general marketing campaigns, and encountered by pediatric dermatologists as assessed by informal survey.
1.1. Moisturizers
Moisturizers encompass a broad group of products that aim to hydrate the skin by reducing transepidermal water loss [6, 7]. There are many different types of moisturizers that vary in terms of occlusivity, esthetic properties, and added ingredients targeting different skin concerns. While moisturizers are generally considered beneficial, many moisturizing products contain ingredients that are comedogenic, such as oleic acid, petrolatum, isopropyl esters, and some emulsifiers [7]. Popular moisturizers may include a variety of trending ingredients with variable levels of evidence behind the claims of their benefits. Some of these ingredients are discussed in Table 1.
TABLE 1.
Common ingredients in cosmeceutical moisturizers.
| Ingredient | Description |
|---|---|
| Ceramides |
|
| Peptides |
|
| Hyaluronic acid (HA) |
|
A moisturizer can be useful to soothe skin irritation; however, adolescents with acne‐prone skin should be directed toward noncomedogenic products [7]. The popular social media trend “slugging” involves applying occlusive or comedogenic products such as petrolatum to purportedly hydrate the skin, which can worsen acne lesions by trapping oil and dirt in the skin. These agents can also trap ingredients from other skincare products, potentially increasing their potency, leading to irritation [14].
All skincare products, including cosmeceuticals of all categories, may contain known contactants that can provoke allergic contact dermatitis in the pediatric population. Examples of common, well‐documented allergens that may be found in cosmeceuticals include fragrances, emollients (such as lanolin and propylene glycol), and preservative ingredients (such as formaldehyde and methylisothiazolinone) [15].
1.2. Anti‐Acne Agents
Acne vulgaris is one of the most common dermatologic concerns among the pediatric population, affecting over 80% of adolescents [7]. Acne‐targeting cosmeceuticals may be beneficial for an acne‐prone consumer. Acne can cause significant psychological distress, driving many pre‐teens and teens to seek relief, which may involve following social media influencers and buying products touting dramatic benefits. It is important for dermatologists to be knowledgeable about cosmeceutical products targeting acne in order to understand what their patients may be using aside from prescribed agents, and to optimally integrate prescription treatments into a regimen their patients will be compliant with and satisfied to use consistently. Common anti‐acne agents and their possible benefits and associated risks can be found in Table 2.
TABLE 2.
Common anti‐acne agents in cosmeceuticals.
| Agent | Description |
|---|---|
| Salicylic acid |
|
| Glycolic acid |
|
| Benzoyl peroxide (BPO) |
|
| Topical vitamin A derivatives (retinoids) |
|
| Azelaic acid |
|
| Hypochlorous acid |
|
| Hydrocolloid patches |
|
1.3. Sunscreen
Broad‐spectrum sunscreen is the most effective cosmeceutical for skin cancer prevention and prevention of skin aging signs [1]. Sunscreen should be recommended to all children and adolescents [1]. Broad‐spectrum sunscreen blocks both long‐wave ultraviolet radiation (UVA), thought to be the primary contributor to photoaging, and short‐wave ultraviolet radiation (UVB), considered to be the main contributor to sunburns and skin cancer [1]. The continuous use of broad‐spectrum sunscreen has been shown in multiple studies to prevent and even reverse signs of photoaging in adults [29]. There are several types of broad‐spectrum sunscreens including those with chemical blockers, mineral blockers, and those that are tinted to match skin tone. In the pediatric population, sunscreen serves a largely protective function in preventing acute sunburn and phototoxicity and thus the chronic effects that lead to photoaging and skin cancer [1]. While many dermatologists might be wary of the overuse of cosmeceutical products by children, the increased interest in sunscreen in this population that has resulted from the popularity of the cosmeceutical industry may help reduce skin cancer rates [1, 30].
1.4. Cleansers
Cleansers are designed to remove sweat, microorganisms, excess sebum, and debris from the surface of the skin [6]. Cleansers often contain surfactants that emulsify and remove these aggregates from the skin, including soaps [7]. While the term “soap” is often used interchangeably with “cleanser”, in this context “soap” refers to anionic surfactants used in some facial cleansers that can be helpful for those with oily skin, but can be too harsh for sensitive skin [7, 31]. Nonionic surfactants found in nonsoap cleansers are generally more mild and less damaging to the stratum corneum, and are preferred for sensitive skin [7, 31].
While cleansing is generally beneficial, over‐cleansing can cause damage to the skin barrier, leading to irritation and an imbalance of the skin microbiome that can worsen acne [7]. Additionally, individuals with allergies or sensitivities to fragrances or harsher surfactants that are found in some facial cleansers may present with irritant contact dermatitis [32]. It is important to mitigate these risks in children and adolescents by recommending a mild cleanser, usually containing an amphoteric (acts as both acid and base) surfactant in the pH range of 4–6 to match the skin's natural acidity [6, 7].
Toners are astringents that are meant to provide additional cleansing benefits to the skin, usually after cleaning the face with a cleanser that is washed off [6, 31]. These may contain alcohol for oily skin or propylene glycol for more sensitive skin [6]. Toners do not confer much additional cleansing benefit if an appropriate facial cleanser is used, and they can be overly drying [6]. Some toners contain anti‐acne or anti‐aging ingredients such as salicylic acid or glycolic acid; these toners may also result in dryness and carry the same risks and potential benefits as discussed in the section on anti‐acne agents [6]. Additional details about common cleanser categories are listed in Table 3.
TABLE 3.
Common types of cosmeceutical cleansers.
| Cleanser type | Description |
|---|---|
| Medicated cleansers |
|
| Natural or traditional cleansers | |
| Toners | |
| Scrubbing cleansers |
1.5. Skin‐Lightening Agents
Skin‐lightening agents, sometimes called “skin‐brightening agents,” aim to treat hyperpigmentation in the skin. Postinflammatory hyperpigmentation (PIH) is a common concern that results from a deposition of melanin in the dermis that occurs after inflammation in the skin, such as from acne or eczema [34]. PIH is more prevalent in people with darker skin tones who have more melanin in their skin at baseline [34]. PIH causes significant distress, with patients and families often reporting more concern regarding the discoloration than for the primary dermatosis. The failure of health care providers to recognize and address this concern may contribute to health care disparities in this population. Likewise, PIH is frequently used as a marketing tool by manufacturers of skin care products whether or not products contain ingredients having activity against hyperpigmentation. Skin‐lightening agents also have the potential to be misused in an attempt to achieve a lighter overall complexion, a topic which will be discussed in greater detail in Part II of this review.
1.5.1. Hydroquinone
Hydroquinone is a phenol that inhibits the conversion of tyrosine to melanin in the skin [34]. Formulations of up to 2% can be found in OTC products. While hydroquinone has been proven to be efficacious in treating hyperpigmentation, even 2% hydroquinone used for a prolonged duration carries the risk of inducing exogenous ochronosis, a condition of excess pigment deposition resulting in unintended additive hyperpigmentation [35, 36]. Although prescription‐strength hydroquinone has been approved for use in patients 12 years and older, it is not recommended that young consumers attempt to treat PIH with hydroquinone without the oversight of a dermatologist.
1.5.2. Kojic Acid
Kojic acid also inhibits the conversion of tyrosine to melanin in the skin [2, 35]. Unlike hydroquinone, kojic acid does not carry additional risks of dyspigmentation from long‐term use [2]. However, kojic acid can cause contact dermatitis, so it should be used cautiously in those with sensitive skin [2, 35, 37]. Studies on the use of kojic acid in the pediatric population are lacking.
1.5.3. Other Agents
Retinoids, topical niacinamide, azelaic acid, and vitamin C all have some degree of skin‐lightening effects that have been observed in clinical studies [37, 38, 39, 40, 41]. The cautions and uncertainties regarding use of these ingredients by the pediatric population are the same as discussed previously and in the following section.
1.5.4. Sunscreen
Sunscreen is essential to treating hyperpigmentation and should be encouraged as a first‐line intervention for PIH [34, 35]. Broad spectrum sunscreens (especially tinted sunscreens) prevent further hyperpigmentation and optimize the fading of existing hyperpigmentation [34, 35].
1.6. Anti‐Aging Agents
The intent of many cosmeceutical products is to slow or reverse signs of aging such as dyspigmentation, fine lines, and wrinkles. While the “anti‐aging” claims of products are heavily used as a marketing tactic, this supposed benefit makes little sense for pediatric consumers who have yet to accumulate signs of skin aging. Additionally, the studies that exist even in the adult population are generally not robust randomized control trials and the endpoints are often not clinically meaningful or appreciable. It is important to be aware of the uses and risks of these ingredients as they are widely incorporated into all types of cosmeceutical products.
1.6.1. Topical Vitamin A Derivatives
Active retinoic acid, a vitamin A derivative, has anti‐aging activity through inhibition of collagen degradation and stimulation of collagen synthesis and cell growth and differentiation [2, 6]. Unlike prescription forms of retinoic acid, many of the retinoids found in cosmeceuticals (especially retinol and retinyl esters) are inactive and there is insufficient data to assume clinical efficacy [1, 2, 6, 24]. Retinoids can cause irritation and photosensitivity [2, 24].
1.6.2. Topical Vitamin C Derivatives
Vitamin C, or L‐ascorbic acid in its active form, acts as an antioxidant in the skin [2, 6]. Vitamin C theoretically protects from UVB damage and reduces thymine dimer formation, a cause of skin cancer [2, 6]. Additionally, vitamin C in the skin promotes collagen production and has anti‐inflammatory properties [2]. However, topical L‐ascorbic acid is unstable and is poorly absorbed in the skin, limiting its efficacy in vivo [40]. Cosmeceutical products may also contain other vitamin C derivatives that are theoretically converted to L‐ascorbic acid in the skin, although further research on these derivatives is necessary [40]. Very little research has been conducted on the use of topical vitamin C in the pediatric population and many of the trials of topical vitamin C in adults have significant study bias and lack clinical evidence of efficacy [40]. Some people may experience skin irritation at higher concentrations of vitamin C; those with sensitive skin or eczema should be instructed to use products with a lower concentration (less than 10%) [2].
1.6.3. Topical Vitamin E Derivatives
Vitamin E is an antioxidant found naturally in the stratum corneum of the skin and may play a role in photoprotection [6, 42]. Some studies have suggested that topical vitamin E used in conjunction with topical vitamin C may have a synergistic antioxidant and photoprotective effect [42]. However, there is a lack of robust clinical trials on topical vitamin E in vivo in both the pediatric and adult populations, and the few adult studies of topical vitamin E alone that exist are ill‐equipped to provide convincing clinical evidence [43]. In fact, a small study of vitamin E used to treat scars found that it was actually associated with a worse‐appearing scar and induced contact dermatitis in a third of patients [44]. While topical vitamin E is a common ingredient in many cosmeceutical products, there have been case reports of contact dermatitis, urticaria and other eruptions after use of topical cosmeceutical vitamin E preparations [42].
1.6.4. Topical Niacinamide
Niacinamide is a coenzyme in the production pathways of collagen, ceramides, elastin and keratin, all of which help maintain the skin's natural elasticity [2]. It is involved in the production of adenosine triphosphate (ATP) and repairing damaged DNA, thus it is marketed in cosmeceuticals to repair photodamage [2]. At concentrations less than 5%, topical niacinamide is well‐tolerated, although people with especially sensitive skin may experience irritation [2]. In studies with rats, high doses of systemic niacinamide caused epigenetic and metabolic alterations [41]. There are very little data on topical niacinamide use in children and adult studies of topical niacinamide efficacy are limited to small trials with limited diversity, subjective endpoints, or confounded by inclusion of other agents [45, 46].
1.6.5. Hyaluronic Acid
Topical hyaluronic acid (HA) has been shown in a limited number of trials to decrease fine lines in older patients [47]. For children and adolescents, who have not yet experienced a decrease in the skin's natural production of HA, the reduction in aging signs is less relevant and the benefits of HA‐containing products are likely limited to moisturization [2].
1.6.6. Snail Mucin
Snail mucin contains a high concentration of hyaluronic acid and has antimicrobial properties [12]. Small initial studies of topically applied snail mucin showed possible benefits of hydration, reduction of fine lines, and improvement in skin elasticity and acne, but further research is required to support the findings from these limited studies [12]. Other claims including antioxidant properties, stimulation of collagen production, cancer suppression, scarring and hyperpigmentation reduction have been studied in vitro only, highlighting the need for more robust data [12]. Snail mucin may trigger allergic reactions due to molecular mimicry of a protein in dust mites, and individuals with shellfish allergies may have cross‐reacting sensitivity [12].
2. Conclusion
Despite the widespread and growing use of cosmeceuticals in the pediatric population, very little testing has been conducted to determine the safety and efficacy of these products specifically for younger skin. This limits the ability of both consumers and dermatologists to evaluate the risks associated with these products as well as the validity of the products' marketing claims for children and adolescents. It is important for dermatologists to recommend evidence‐based ingredients to their patients where possible, while also working to preserve and optimize the patient‐provider relationship. Being open to discussing cosmeceutical products with patients, providing reasonable recommendations where appropriate, and not belittling or demeaning a patient's desire for a skin care regimen may improve the patient experience as well as a patient's trust in their provider. Young consumers receive an onslaught of marketing from skincare brands and social media influencers trying to convince them that they need elaborate regimens; dermatologists can work to balance this with advice to keep skincare routines simple and effective.
Conflicts of Interest
The authors declare no conflicts of interest.
Acknowledgments
The authors have nothing to report.
Funding: The authors received no specific funding for this work.
Contributor Information
Gabrielle Keller Goff, Email: gkeller@uchicagomedicine.org.
Sarah L. Stein, Email: sstein@bsd.uchicago.edu.
Data Availability Statement
Data sharing are not applicable to this article as no new data were created or analyzed in this study.
References
- 1. Pham A. K. and Dinulos J. G., “Cosmeceuticals for Children: Should You Care?,” Current Opinion in Pediatrics 26, no. 4 (2014): 446–451, 10.1097/MOP.0000000000000105. [DOI] [PubMed] [Google Scholar]
- 2. Crous C., Pretorius J., and Petzer A., “Overview of Popular Cosmeceuticals in Dermatology,” Skin Health and Disease 4, no. 2 (2024): e340, 10.1002/ski2.340. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Aslan Kayıran M., Karadağ A. S., Alyamaç G., et al., “Social Media Use in Patients With Acne Vulgaris: What Do Patients Expect From Social Media?,” Journal of Cosmetic Dermatology 20, no. 8 (2021): 2556–2564, 10.1111/jocd.14272. [DOI] [PubMed] [Google Scholar]
- 4. Thang C. J., Garate D., Thang J., Lipoff J. B., and Barbieri J. S., “Short‐Form Medical Media: A Multi‐Platform Analysis of Acne Treatment Information in TikTok Videos, Instagram Reels, and YouTube Shorts,” JMIR Dermatology 6, no. 1 (2023): e48140, 10.2196/48140. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. AMR , “Skincare Market Size and Share|Statistics Report – 2031: Allied Market Research,” accessed May 7, 2024, https://www.alliedmarketresearch.com/skincare‐market‐A31878.
- 6. Draelos Z. D., “Cosmeceuticals: What's Real: What's Not,” Dermatologic Clinics 37, no. 1 (2019): 107–115, 10.1016/j.det.2018.07.001. [DOI] [PubMed] [Google Scholar]
- 7. Goodman G., “Cleansing and Moisturizing in Acne Patients,” American Journal of Clinical Dermatology 10, no. 1 (2009): 1, 10.2165/0128071-200910001-00001. [DOI] [PubMed] [Google Scholar]
- 8. Chandan N., Rajkumar J. R., Shi V. Y., and Lio P. A., “A New Era of Moisturizers,” Journal of Cosmetic Dermatology 20, no. 8 (2021): 2425–2430, 10.1111/jocd.14217. [DOI] [PubMed] [Google Scholar]
- 9. Hensley D. and Meckfessel M. H., “Tolerability of a Skin Care Regimen Formulated for Acne‐Prone Skin in Children,” Pediatric Dermatology 32, no. 4 (2015): 501–505, 10.1111/pde.12607. [DOI] [PubMed] [Google Scholar]
- 10. Kraeling M. E. K., Zhou W., Wang P., and Ogunsola O. A., “In Vitro Skin Penetration of Acetyl Hexapeptide‐8 From a Cosmetic Formulation,” Cutaneous and Ocular Toxicology 34, no. 1 (2015): 46–52, 10.3109/15569527.2014.894521. [DOI] [PubMed] [Google Scholar]
- 11. Abu Samah N. H. and Heard C. M., “Topically Applied KTTKS: A Review,” International Journal of Cosmetic Science 33, no. 6 (2011): 483–490, 10.1111/j.1468-2494.2011.00657.x. [DOI] [PubMed] [Google Scholar]
- 12. Singh N., Brown A. N., and Gold M. H., “Snail Extract for Skin: A Review of Uses, Projections, and Limitations,” Journal of Cosmetic Dermatology 23, no. 4 (2024): 1113–1121, 10.1111/jocd.16269. [DOI] [PubMed] [Google Scholar]
- 13. Widgerow A. D., Ziegler M. E., Garruto J. A., et al., “Designing Topical Hyaluronic Acid Technology – Size Does Matter…,” Journal of Cosmetic Dermatology 21, no. 7 (2022): 2865–2870, 10.1111/jocd.15027. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Pagani K., Lukac D., Martinez R., Jablon K., and McGee J. S., “Slugging: TikTok as a Source of a Viral ‘Harmless’ Beauty Trend,” Clinics in Dermatology 40, no. 6 (2022): 810–812, 10.1016/j.clindermatol.2022.08.005. [DOI] [PubMed] [Google Scholar]
- 15. Neale H., Garza‐Mayers A. C., Tam I., and Yu J., “Pediatric Allergic Contact Dermatitis. Part I: Clinical Features and Common Contact Allergens in Children,” Journal of the American Academy of Dermatology 84, no. 2 (2021): 235–244, 10.1016/j.jaad.2020.11.002. [DOI] [PubMed] [Google Scholar]
- 16. Tang S. C. and Yang J. H., “Dual Effects of Alpha‐Hydroxy Acids on the Skin,” Molecules 23, no. 4 (2018): 863, 10.3390/molecules23040863. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Mohsin N., Hernandez L. E., Martin M. R., Does A. V., and Nouri K., “Acne Treatment Review and Future Perspectives,” Dermatologic Therapy 35, no. 9 (2022): e15719, 10.1111/dth.15719. [DOI] [PubMed] [Google Scholar]
- 18. Kucera K., Zenzola N., Hudspeth A., et al., “Benzoyl Peroxide Drug Products Form Benzene,” Environmental Health Perspectives 132, no. 3 (2024): 037702, 10.1289/EHP13984. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Barbieri J. S., Streicher J. L., and Rosmarin D., “Benzene in Benzoyl Peroxide‐How Worried Should We Be?,” Journal of the American Academy of Dermatology 91, no. 4 (2024): 772–773, 10.1016/j.jaad.2024.05.093. [DOI] [PubMed] [Google Scholar]
- 20. Del Rosso J. Q., “Benzoyl Peroxide, Benzene, and Lots of Unanswered Questions: Where Are We Now?,” Cutis 114, no. 1 (2024): 3, 10.12788/cutis.1043. [DOI] [PubMed] [Google Scholar]
- 21. Garate D., Thang C. J., Lai J., Golovko G., Wilkerson M. G., and Barbieri J. S., “Benzoyl Peroxide for Acne Treatment Is Not Associated With an Increased Risk of Malignancy: A Retrospective Cohort Study,” Journal of the American Academy of Dermatology 91, no. 5 (2024): 966–968, 10.1016/j.jaad.2024.07.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Sadr N., Troger A., Chai P. R., and Barbieri J. S., “No Evidence for an Association Between Benzoyl Peroxide Use and Increased Blood Benzene Levels in the National Health and Nutrition Examination Survey,” Journal of the American Academy of Dermatology 91, no. 4 (2024): 763–765, 10.1016/j.jaad.2024.06.050. [DOI] [PubMed] [Google Scholar]
- 23. Cunliffe W. J., Poncet M., Loesche C., and Verschoore M., “A Comparison of the Efficacy and Tolerability of Adapalene 0·1% Gel Versus Tretinoin 0·025% Gel in Patients With Acne Vulgaris: A Meta‐Analysis of Five Randomized Trials,” British Journal of Dermatology 139, no. S52 (1998): S48–S56, 10.1046/j.1365-2133.1998.1390s2048.x. [DOI] [PubMed] [Google Scholar]
- 24. Saurat J. H. and Sorg O., “Retinoids,” in European Handbook of Dermatological Treatments, eds. Katsambas A. D., Lotti T. M., Dessinioti C., and D'Erme A. M. (London, UK: Springer International Publishing, 2023), 1741–1761, 10.1007/978-3-031-15130-9_154. [DOI] [Google Scholar]
- 25. Katsambas A., Graupe K., and Stratigos J., “Clinical Studies of 20% Azelaic Acid Cream in the Treatment of Acne Vulgaris. Comparison With Vehicle and Topical Tretinoin,” Acta Dermato‐Venereologica 69 (1989): 35–39, 10.2340/000155551433539. [DOI] [PubMed] [Google Scholar]
- 26. Natarelli N., Nong Y., Maloh J., and Sivamani R., “Hypochlorous Acid: Applications in Dermatology,” Journal of Integrative Dermatology (2022). [Google Scholar]
- 27. Thomas S., “Hydrocolloid Dressings in the Management of Acute Wounds: A Review of the Literature,” International Wound Journal 5, no. 5 (2008): 602–613, 10.1111/j.1742-481X.2008.00541.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Kosmoski G., Du‐Soriano J., Ilg D., DelSasso A., and Zhang P., “50551 the Science Behind a Viral Trend: Demonstrating Safety and Efficacy of Hydrocolloid Patch for Facial Acne,” Journal of the American Academy of Dermatology 91, no. 3 (2024): AB336, 10.1016/j.jaad.2024.07.1336. [DOI] [Google Scholar]
- 29. Krutmann J., Schalka S., Watson R. E. B., Wei L., and Morita A., “Daily Photoprotection to Prevent Photoaging,” Photodermatology, Photoimmunology & Photomedicine 37, no. 6 (2021): 482–489, 10.1111/phpp.12688. [DOI] [PubMed] [Google Scholar]
- 30. Rajagopal G., Talluri R., Chuy V. S., Cheng A. L., and Dall L., “Trends in Sunscreen Use Among US Middle and High School Students, 2007–2019,” Cureus 13, no. 7 (2021): e16468, 10.7759/cureus.16468. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Draelos Z. D., “The Science Behind Skin Care: Cleansers,” Journal of Cosmetic Dermatology 17, no. 1 (2018): 8–14, 10.1111/jocd.12469. [DOI] [PubMed] [Google Scholar]
- 32. Zirwas M. J., “Contact Dermatitis to Cosmetics,” Clinical Reviews in Allergy and Immunology 56, no. 1 (2019): 119–128, 10.1007/s12016-018-8717-9. [DOI] [PubMed] [Google Scholar]
- 33. Guerranti C., Martellini T., Perra G., Scopetani C., and Cincinelli A., “Microplastics in Cosmetics: Environmental Issues and Needs for Global Bans,” Environmental Toxicology and Pharmacology 68 (2019): 75–79, 10.1016/j.etap.2019.03.007. [DOI] [PubMed] [Google Scholar]
- 34. Cestari T. F., Dantas L. P., and Boza J. C., “Acquired Hyperpigmentations,” Anais Brasileiros de Dermatologia 89, no. 1 (2014): 11–25, 10.1590/abd1806-4841.20142353. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Callender V. D., Barbosa V., Burgess C. M., et al., “Approach to Treatment of Medical and Cosmetic Facial Concerns in Skin of Color Patients,” Skin Color 100, no. 6 (2017): 375–380. [PubMed] [Google Scholar]
- 36. Gandhi V., Verma P., and Naik G., “Exogenous Ochronosis After Prolonged Use of Topical Hydroquinone (2%) in a 50‐Year‐Old Indian Female,” Indian Journal of Dermatology 57, no. 5 (2012): 394–395, 10.4103/0019-5154.100498. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37. Kindred C., Okereke U., and Callender V. D., “Skin‐Lightening Agents: An Overview of Prescription, Office‐Dispensed, and Over‐the‐Counter Products,” Cutis 26, no. 5 (2013): 18–26. [Google Scholar]
- 38. Zaenglein A. L., Pathy A. L., Schlosser B. J., et al., “Guidelines of Care for the Management of Acne Vulgaris,” Journal of the American Academy of Dermatology 74, no. 5 (2016): 945–973.e33, 10.1016/j.jaad.2015.12.037. [DOI] [PubMed] [Google Scholar]
- 39. Guan L. L., Lim H. W., and Mohammad T. F., “Sunscreens and Photoaging: A Review of Current Literature,” American Journal of Clinical Dermatology 22, no. 6 (2021): 819–828, 10.1007/s40257-021-00632-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40. Enescu C. D., Bedford L. M., Potts G., and Fahs F., “A Review of Topical Vitamin C Derivatives and Their Efficacy,” Journal of Cosmetic Dermatology 21, no. 6 (2022): 2349–2359, 10.1111/jocd.14465. [DOI] [PubMed] [Google Scholar]
- 41. Boo Y. C., “Mechanistic Basis and Clinical Evidence for the Applications of Nicotinamide (Niacinamide) to Control Skin Aging and Pigmentation,” Antioxidants 10, no. 8 (2021): 1315, 10.3390/antiox10081315. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42. Burke K. E., “Interaction of Vitamins C and E as Better Cosmeceuticals,” Dermatologic Therapy 20, no. 5 (2007): 314–321, 10.1111/j.1529-8019.2007.00145.x. [DOI] [PubMed] [Google Scholar]
- 43. Thiele J. J., Hsieh S. N., and Ekanayake‐Mudiyanselage S., “Vitamin E: Critical Review of Its Current Use in Cosmetic and Clinical Dermatology,” Dermatologic Surgery 31, no. S1 (2005): S805–S813, 10.1111/j.1524-4725.2005.31724. [DOI] [PubMed] [Google Scholar]
- 44. Baumann L. S. and Spencer J., “The Effects of Topical Vitamin E on the Cosmetic Appearance of Scars,” Dermatologic Surgery 25, no. 4 (1999): 311–315, 10.1046/j.1524-4725.1999.08223.x. [DOI] [PubMed] [Google Scholar]
- 45. Lee D. H., Oh I. Y., Koo K. T., et al., “Reduction in Facial Hyperpigmentation After Treatment With a Combination of Topical Niacinamide and Tranexamic Acid: A Randomized, Double‐Blind, Vehicle‐Controlled Trial,” Skin Research and Technology 20, no. 2 (2014): 208–212, 10.1111/srt.12107. [DOI] [PubMed] [Google Scholar]
- 46. Bissett D. L., Oblong J. E., and Berge C. A., “Niacinamide: A B Vitamin That Improves Aging Facial Skin Appearance,” Dermatologic Surgery 31, no. 7 (2005): 860–865, 10.1111/j.1524-4725.2005.31732. [DOI] [PubMed] [Google Scholar]
- 47. Bravo B., Correia P., Gonçalves Junior J. E., et al., “Benefits of Topical Hyaluronic Acid for Skin Quality and Signs of Skin Aging: From Literature Review to Clinical Evidence,” Dermatologic Therapy 35, no. 12 (2022): e15903, 10.1111/dth.15903. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Data sharing are not applicable to this article as no new data were created or analyzed in this study.
